BAGNEAUX, France--(BUSINESS WIRE)--Regulatory News: DBV Technologies (Paris:DBV) (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Pr. Hugh Sampson to its world-class Scientific Advisory Board. In joining the Scientific Advisory Board, Pr. Sampson will provide DBV Technologies with access to his unique expertise in food allergy. Pr. Sampson’s appointment is of strategic importance to DBV Technologies, as the Company works towards the completion of ongoing clinical studies as well as the initiation of several additional clinical studies in peanut and milk allergies.
